Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
0.66 EUR
304.94 M EUR
3.82 B EUR
343.39 M
About NOVONESIS (NOVOZYMES A/S) B
Sector
CEO
Ester Baiget
Headquarters
Lyngby
Website
ISIN
DK0060336014
FIGI
BBG00KDZJQK3
Novonesis A/S engages in the era of biosolutions. It innovate and develop transformative biosolutions that improve the way the world produces, consumes, and lives. The company was founded on January 29, 2024 is headquartered in Lyngby, Denmark.
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of NZYM is 58.04 EUR — it has increased by 1.31% in the past 24 hours. Watch NOVOZYMES AS stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on VIE exchange NOVOZYMES AS stocks are traded under the ticker NZYM.
NZYM stock has risen by 9.01% compared to the previous week, the month change is a 6.68% rise, over the last year NOVOZYMES AS has showed a 9.88% increase.
We've gathered analysts' opinions on NOVOZYMES AS future price: according to them, NZYM price has a max estimate of 80.19 EUR and a min estimate of 52.03 EUR. Watch NZYM chart and read a more detailed NOVOZYMES AS stock forecast: see what analysts think of NOVOZYMES AS and suggest that you do with its stocks.
NZYM reached its all-time high on Jan 3, 2022 with the price of 72.76 EUR, and its all-time low was 35.86 EUR and was reached on Jan 25, 2019. View more price dynamics on NZYM chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
NZYM stock is 1.27% volatile and has beta coefficient of 0.20. Track NOVOZYMES AS stock price on the chart and check out the list of the most volatile stocks — is NOVOZYMES AS there?
Today NOVOZYMES AS has the market capitalization of 27.35 B, it has increased by 8.34% over the last week.
Yes, you can track NOVOZYMES AS financials in yearly and quarterly reports right on TradingView.
NOVOZYMES AS is going to release the next earnings report on Aug 21, 2025. Keep track of upcoming events with our Earnings Calendar.
NZYM earnings for the last half-year are 0.91 EUR per share, whereas the estimation was 1.05 EUR, resulting in a −13.13% surprise. The estimated earnings for the next half-year are 0.58 EUR per share. See more details about NOVOZYMES AS earnings.
NOVOZYMES AS revenue for the last half-year amounts to 2.00 B EUR, despite the estimated figure of 2.02 B EUR. In the next half-year revenue is expected to reach 2.13 B EUR.
NZYM net income for the last half-year is 241.25 M EUR, while the previous report showed 63.76 M EUR of net income which accounts for 278.39% change. Track more NOVOZYMES AS financial stats to get the full picture.
As of Mar 5, 2025, the company has 10.58 K employees. See our rating of the largest employees — is NOVOZYMES AS on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. NOVOZYMES AS EBITDA is 1.18 B EUR, and current EBITDA margin is 30.77%. See more stats in NOVOZYMES AS financial statements.
Like other stocks, NZYM shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade NOVOZYMES AS stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So NOVOZYMES AS technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating NOVOZYMES AS stock shows the buy signal. See more of NOVOZYMES AS technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.